LABEST 2021 - DAY ONE

LABEST DAY 1 - Tuesday, May 25th

11:00AM - UCLA CHANCELLOR BLOCK WELCOME ADDRESS

11:00 - 11:30AM - KEYNOTE ADDRESS: WHY L.A. 

Los Angeles' attraction as a bioscience ecosystem, its exciting growth, competitive advantages, and its future including hosting the 2028 Summer Olympics, LA28.

	Eric Esrailian, Chief Vatche & Tamar Manoukian Division of Digestive Diseases, UCLA Health
	Gene Sykes, Co-Chairman of Global Mergers & Acquisitions, Co-Chairman, Global, Technology and Media Telecom Group, Goldman Sachs
	Jaime Lee, President of the Board of Harbor Commissioners for the Port of Los Angeles, Chief Executive Officer, Jamison Realty & Board Member of LA28

11:30AM - 11:35AM OPENING REMARKS

David Piacquad, Senior Vice President, Business Development, AMGEN

11:35AM - 12:20PM - GROWTH AND RETENTION OF BIOTECH START-UPS IN LOS ANGELES - THE LUNDQUIST INSTITUTE STARTUP AUDITORIUM  Bioscience CEOs will discuss their experiences, decisions, challenges and future opportunities with being located in Los Angeles

	Moderator: Peter Moglia, Co-CEO & Co-Chief Investment Officer, Alexandria Real Estate Equities, Inc.
	Bassil Dahiyat, Chief Executive Officer, Xencor
	Richard Markus, Chief Executive Officer, Dantari Pharmaceuticals
	JJ Kang, Chief Executive Officer, Appia Bio
	Hallie Kuhn, Principal, Science & Technology, Alexandria Real Estate Equities, Inc.
	Dave Licata, President & CEO, 1200 Pharma & TORL Therapeutics

12:00PM - 1:15PM MEET LEADERS IN THE BUSINESS OF LIFE SCIENCES - AMGEN AUDITORIUM 

	Moderator: Arie Belldegrun, Chief Executive Officer, Bellco Capital
	Christi Shaw - Chief Executive Officer, Kite, A Gilead Company
	David Chang - Chief Executive Office, Allogene Therapeutics
	Craig Gordon - MD, MBA, Former Partner, Capital Group
	Daphne Koller - Chief Executive Officer, insitro
	Levi Garraway - Chief Medical Officer, Genentech

1:00PM - 1:45PM - CIRM STRATEGIC PRIORITIES & OPPORTUNITIES BEYOND 2020 - KITE, A GILEAD COMPANY AUDITORIUM

With the passage of Prop 14, an additional $5.5 billion dollars have been allocated to fund stem cell research. Leaders in the field will discuss strategy and new opportunities in neuropsychiatric and other disorders.

	Moderator: S. Thomas Carmichael, Professor & Frances Stark Endowed Chair, Department of Neurology, Acting Director, Broad Stem Cell Research Center
	Maria Millan, President & CEO, California Institute for Regenerative Medicine
	Andy McMahon, Director of Eli & Edythe Broad CIRM Center for Regenerative Medicine & Stem Cell Research at USC
	John Zaia, Director for the Center of Gene Therapy, City of Hope
	Al Rowlett, CEO Turning Point Community Programs

1:30 - 2:15 AMGEN R&D/ ACADEMIC STRATEGIES - AMGEN AUDITORIUM 

Industry leaders discuss how to strategically work with academia to develop a pipeline for research, development and talent.

	Moderator: John Mazziotta, Vice Chancellor UCLA Health Sciences, CEO, UCLA Health
	Ray Deshaies, Head of Global Research, AMGEN
	Philip Tagari, Head of Therapeutic Discovery Research, AMGEN
	Tara Arvedson, Executive Director, Oncology Research & Global Fastlane Network Lead, AMGEN
	Chetan Goudar, Vice President, Process Development, AMGEN
	Saptarsi Haldar, Vice President, Cardiometabolic Disorders, AMGEN

2:00PM - 2:30PM : HOW KITE, A GILEAD COMPANY IS BUILDING A GLOBAL CAR-T FRANCHISE OUT OF LOS ANGELES 

Learn how Kite's focus on cell therapy to treat cancer has advanced industry-leading pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates to treat both hematological cancers and solid tumors.

	Moderator: Antonio Bernardo - Dean, Anderson School of Business, UCLA
	Francesco Marincola, Global Head of Cell Therapy Research, Kite, A Gilead Company
	Frank Neumann, Global Head of Clinical Development, Kite, Gilead Company
	Matt Hostetler, Vice President, Head of Human Resources, Kite, A Gilead Company
	Mert Aktar, Vice President, Head of Corporate Development, Kite, A Gilead Company